<DOC>
	<DOCNO>NCT00006441</DOCNO>
	<brief_summary>The purpose study see whether take interleukin-2 ( IL-2 ) anti-HIV drug affect course HIV disease patient primary HIV infection ( time period immediately follow infection HIV ) . After primary HIV infection , actual infection spread increase amount HIV virus body . Studies show , take combination anti-HIV drug , possible reduce amount HIV body almost undetectable level . This study find starting anti-HIV drug primary infection interrupt reduce spread HIV patient ' body .</brief_summary>
	<brief_title>Effectiveness Adding Interleukin-2 Anti-HIV Drugs Patients Recently Infected With HIV</brief_title>
	<detailed_description>Following initial exposure HIV , infection establish rapid replication homogeneous strain virus . Preliminary study combination antiretroviral therapy show possible reduce circulate HIV RNA detectable level phase . Sustained suppression viral replication viral eradication may possible HIV become integrate immune system undergone number quasi specie mutation . This study assess feasibility interrupt natural course HIV infection use antiretroviral therapy soon initial infection . Nelfinavir ( NFV ) zidovudine/lamivudine ( Combivir ) treatment start soon possible , 7 day diagnosis HIV infection , continue 104 week . After 4 week therapy patient randomize begin receive IL-2 therapy delay start Week 48 . Patients may choose receive IL-2 treatment remain study . Patients clinic visit measure viral load every 4 week . At final clinic visit , physical examination collection semen , cervical fluid , blood , saliva specimen do . Eligible consent patient tonsil biopsy . Patients reimburse participation study .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Have recent HIV infection . Are available followup least 96 week . Are least 18 year old . Use barrier method birth control . Exclusion Criteria Patients eligible study : Have condition EpsteinBarr virus , CMV mononucleosis syndrome , acute streptococcal pharyngitis . Have take antiHIV therapy 4 week . Have cancer require chemotherapy radiation therapy within 1 month study entry yet recover effect . Abuse alcohol drug . Are pregnant . Have condition interferes intestinal absorption , severe diarrhea .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Virus Replication</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Interleukin-2</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>CD4-Positive T-Lymphocytes</keyword>
	<keyword>CD8-Positive T-Lymphocytes</keyword>
	<keyword>Biological Markers</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Nelfinavir</keyword>
	<keyword>Cytotoxicity , Immunologic</keyword>
	<keyword>Acute Infection</keyword>
</DOC>